Basic Suprax Information

• INN (International Nonproprietary Name): Cefixime.
• Brand Names Available In United Kingdom: Suprax and generics (Suprax, Cefspan, Cefix and others); local packaging varies between blister packs for tablets and bottles for suspension.
• ATC Code: J01DD08 — Third‑generation cephalosporin antibiotic for systemic bacterial infections.
• Forms & Dosages: Tablets 400 mg; capsules 400 mg; chewable tablets 100 mg and 200 mg; oral suspension 100 mg/5 mL and 200 mg/5 mL.
• Manufacturers In United Kingdom: Not specified in supplied data; global suppliers include Lupin, Aurobindo, Cipla, Dr. Reddy’s, Egis, Krka and Teva.
• Registration Status In United Kingdom: Prescription‑only with various national registrations in Europe; see national regulators for up‑to‑date status.
• OTC / Rx Classification: Prescription‑only (Rx) in all observed markets.

Key Findings From Recent Trials

Major 2022–2025 Studies

Clinicians ask whether cefixime remains useful given changing resistance patterns.

Recent surveillance and clinical literature from 2022–24 highlight two clear trends affecting cefixime use.

First, public‑health surveillance has documented rising reduced susceptibility in Neisseria gonorrhoeae to oral third‑generation cephalosporins.

Second, real‑world data continue to show satisfactory effectiveness for many common community infections when cefixime is chosen appropriately.

Main Outcomes

Large datasets from WHO, ECDC and national public‑health laboratories report increasing minimum inhibitory concentrations against cefixime for gonococci.

Those trends have led to guideline shifts away from oral cefixime monotherapy for gonorrhoea in many jurisdictions.

Observational cohorts and meta‑analyses for uncomplicated urinary tract infection and paediatric otitis media indicate comparable short‑course cure rates versus older comparators when local susceptibility supports use.

Paediatric practice benefits from oral suspension formulations and once‑daily dosing, which aid adherence and make cefixime attractive where amoxicillin is not suitable.

Overall evidence strength is moderate for UTI and otitis, and lower for gonorrhoea efficacy because of evolving resistance.

Clinicians in the United Kingdom should always interpret these findings against local antibiograms and current NICE and UKHSA guidance before choosing cefixime or Suprax.

Safety surveillance continues to show the expected pattern of gastrointestinal adverse events and rare serious hypersensitivity reactions.

The documented risk of Clostridioides difficile infection remains low but is recognised and warrants vigilance.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how Suprax works in plain terms.

Cefixime is an oral third‑generation cephalosporin that stops bacteria from building a protective cell wall.

Without a proper cell wall the bacteria cannot maintain their integrity and they die.

It is supplied as tablets, capsules or suspension for systemic treatment of common bacterial infections.

Scientific Breakdown

Cefixime binds penicillin‑binding proteins that mediate peptidoglycan cross‑linking in the bacterial cell wall.

Binding inhibits transpeptidation and disrupts cell‑wall synthesis, producing bactericidal effects.

The antimicrobial spectrum is stronger against many Gram‑negative bacteria and selected Gram‑positive species.

Cefixime is less active against Pseudomonas than some other beta‑lactams.

Oral bioavailability is moderate and supports once‑daily 400 mg dosing or twice‑daily 200 mg regimens depending on clinical preference and formulation.

PK/PD Notes

Protein binding is moderate and renal excretion is the dominant elimination pathway.

Dose reduction is advised when creatinine clearance is below 60 mL/min.

Cefixime displays time‑dependent killing, so clinical effectiveness relates to the duration plasma concentrations remain above the MIC.

Consistent dosing and appropriate renal adjustment improve clinical outcomes and safety.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Prescribers commonly see Suprax and cefixime listed in formularies for systemic bacterial infections.

Approved indications typically include uncomplicated urinary tract infection, acute otitis media, pharyngitis/tonsillitis and selected respiratory infections.

Historically cefixime was used as a single‑dose option for uncomplicated gonorrhoea in some places, but rising resistance has changed that approach.

Formulations supplied through international and UK supply chains include 400 mg tablets, chewable 100 mg and 200 mg tablets and paediatric oral suspensions 100 mg/5 mL.

Notable Off‑Label Trends

Off‑label prescribing commonly appears in travel medicine when an oral agent is required overseas or at short notice.

Paediatric use of suspension is a common option where amoxicillin is contraindicated due to allergy.

Empirical community use for urinary infections is seen when local resistance data support a broad Gram‑negative agent.

All off‑label decisions should be justified by local susceptibility, stewardship principles and documented rationale in the clinical record.

Dosage Strategy

General Dosing

Typical adult dosing in community practice is 400 mg once daily or 200 mg every 12 hours.

Treatment durations usually run from five to ten days for most infections.

Single‑dose 400 mg was used historically for uncomplicated gonorrhoea but is now rarely recommended due to resistance concerns.

Paediatric dosing for children aged six months to 12 years is 8 mg/kg once daily or 4 mg/kg every 12 hours using the 100 mg/5 mL or 200 mg/5 mL suspensions.

Condition‑Specific Dosing

• Uncomplicated UTI: 400 mg once daily or 200 mg twice daily for three to seven days depending on severity and culture results.
• Otitis Media: 400 mg once daily, typically for five to ten days.
• Pharyngitis/Tonsillitis: 400 mg once daily for five to ten days.
• Gonorrhoea: historical single 400 mg dose; check current UKHSA and NICE guidance before use.
• Renal Impairment: reduce dose by approximately 50% if creatinine clearance is less than 60 mL/min.

Elderly patients require close monitoring of renal function to guide dose adjustments and avoid accumulation.

Safety Protocols

Contraindications

Absolute contraindications include known severe hypersensitivity to cefixime, other cephalosporins or formulation excipients.

A history of severe immediate penicillin anaphylaxis warrants caution because of potential cross‑reactivity.

Safety and efficacy in children under six months have not been established and use is not recommended in that age group.

Use caution and monitor closely in renal impairment and in severe hepatic disease.

Adverse Effects

Common adverse effects include diarrhoea, abdominal pain, flatulence, dyspepsia, headache, nausea and rash.

Less common but serious reactions include anaphylaxis, Stevens–Johnson syndrome, blood dyscrasias and C. difficile colitis.

Discontinue cefixime immediately if severe cutaneous adverse reactions or signs of severe hypersensitivity occur.

Pregnancy is a cautious indication described in product monographs as category B, so prescribe only when clearly indicated and after obstetric consultation where appropriate.

Interaction Mapping

Food Interactions

Take cefixime with or without food.

Food may modestly delay absorption but does not substantially reduce overall exposure, which supports dosing flexibility and adherence, particularly in children on suspension.

Drug Combinations To Avoid

• Probenecid decreases renal tubular secretion of cefixime and raises serum levels; monitoring may be required.
• Anticoagulants such as warfarin can have an increased bleeding risk when given with cephalosporins; monitor INR.
• Concurrent nephrotoxic agents, for example aminoglycosides or high‑dose loop diuretics, may increase renal risk and require renal monitoring.
• There is no consistent clinical evidence that cefixime reduces oral contraceptive efficacy, but counsel patients about the theoretical risk and advise additional contraception if concerned.

Review concomitant medicines and renal function before prescribing cefixime or Suprax.

Patient Experience Analysis

Survey Data

Patients prefer once‑daily regimens because they are easier to remember and have better completion rates.

The availability of Suprax suspension is frequently mentioned positively in paediatric adherence studies.

Common patient complaints include gastrointestinal upset and dislike of the suspension taste.

Clear instructions on missed doses improve adherence; when a dose is missed patients should take it as soon as they remember unless the next dose is due, and should not double up.

Forum Trends

Parent groups and online forums often ask about Suprax syrup for children and how it compares to alternatives for taste and tolerability.

Posts commonly raise concerns about allergic reactions and what to do if side effects appear.

Pharmacists should proactively counsel caregivers on reconstitution, refrigeration of suspension and to discard after 14 days.

Explain the stewardship reasons for choosing cefixime and when alternative antibiotics are preferred.

Distribution & Pricing Landscape

Suprax and cefixime are supplied globally by manufacturers such as Lupin, Aurobindo, Cipla, Dr. Reddy’s, Egis, Krka and Teva.

In the United Kingdom the product is typically available as generics and occasional branded packs, with blistered tablets and suspension bottles being common packaging formats.

Pricing varies across community pharmacies and NHS procurement, which leads to a preference for generics on cost grounds.

Storage for tablets is at controlled room temperature and reconstituted suspension must be refrigerated and used within 14 days.

Procurement teams should monitor manufacturer recalls and stock levels, as shortages of oral antibiotics can occur periodically.

Alternative Options

Comparison Summary

Cefpodoxime offers a similar third‑generation spectrum and is frequently dosed twice daily.

Cefuroxime provides broader Gram‑positive coverage and is used commonly for respiratory infections.

Cefdinir is another oral third‑generation option but paediatric suspensions may have taste complaints.

Amoxicillin/clavulanate provides broader anaerobic and β‑lactamase coverage but carries a higher diarrhoea risk.

Pros And Cons

Cefixime advantages include once‑daily dosing, good Gram‑negative coverage and paediatric suspension availability.

Limitations are reduced activity against some resistant gonococci, lower potency against certain Gram‑positives and a potential C. difficile risk.

For uncomplicated UTI in the UK, first‑line narrow‑spectrum agents such as nitrofurantoin or trimethoprim (where appropriate) are generally preferred.

Reserve cefixime for specific indications supported by culture data or where allergy to first‑line agents exists.

Regulatory Status

Global Approvals & Notes

Cefixime has long‑standing registration in multiple jurisdictions, including FDA approval first authorised in 1986.

Health Canada lists DINs for 400 mg tablets and 100 mg/5 mL suspension.

Cefixime also appears on the WHO Essential Medicines List, reflecting its global clinical importance.

United Kingdom Specifics

In the UK cefixime is prescription‑only and is incorporated into national formularies in appropriate clinical roles.

Prescribers should follow NICE and UKHSA guidance and local antibiograms, particularly for gonorrhoea where cefixime is no longer first‑line in many cases.

Adverse reactions should be reported via the Yellow Card scheme to support pharmacovigilance.

Consolidated FAQ

Quick Answers Clinicians And Patients Search For

Can I take Suprax with food? Yes; food may delay absorption slightly but does not reduce efficacy.

Is it safe in pregnancy? Product monographs indicate pregnancy category B; use only if clearly indicated and after obstetric consultation.

What if I miss a dose? Take it as soon as remembered unless the next dose is due; do not double up.

How long to keep reconstituted suspension? Refrigerate and discard after 14 days.

Can it be used for gonorrhoea? Rising resistance has reduced recommendations for cefixime monotherapy; follow UKHSA and NICE guidance.

For suspected severe allergies or serious adverse effects patients should seek urgent medical care or contact their GP.

Visual Guide

Suggested Figures And Infographics

Include a simple mechanism schematic showing cefixime binding PBPs and inhibiting cell‑wall synthesis in a three‑panel animation.

Create a dosing chart for adults and paediatrics with renal adjustment thresholds and recommended dose modifications.

Provide a resistance heatmap for N. gonorrhoeae using the latest ECDC and UKHSA surveillance figures to aid prescriber decisions.

Labelling And Packaging Visuals

High‑resolution mockups should show blister pack labels for 400 mg tablets and suspension bottle labels including storage and reconstitution instructions.

Visuals can include common adverse signs such as rash and severe diarrhoea and a Yellow Card reporting QR code for UK patients.

Use clear image alt text, for example “Suprax 400 mg tablet UK label”, to support SEO and accessibility.

Storage & Transport

Recommended Conditions

Store tablets and capsules at controlled room temperature, typically between 15 °C and 30 °C, protected from moisture and light.

Keep unreconstituted suspension at room temperature until required for reconstitution at the pharmacy or at home.

Reconstitution & Cold Chain Notes

Once the oral suspension is reconstituted, refrigerate and instruct caregivers to discard any unused portion after 14 days.

During transport avoid prolonged heat exposure for bottles of suspension, especially during summer months.

Pharmacies should rotate stock using first‑in, first‑out practices and keep expiry dates clearly visible.

Guidelines For Proper Use

Prescribing Best Practices

Confirm bacterial aetiology where feasible and use narrow‑spectrum agents first if clinically appropriate.

Reserve cefixime for indications that local susceptibility supports or where first‑line agents are contraindicated.

Provide patients with written dosing instructions, missed‑dose guidance and an allergy action plan when required.

Antimicrobial Stewardship & Resistance Mitigation

Use the shortest effective duration of therapy, commonly five to ten days, and avoid prescribing for likely viral illnesses such as most URTIs.

Document indication and review culture results promptly to de‑escalate therapy if appropriate.

Report treatment failures and unusual resistance patterns to local public‑health bodies to support surveillance.

Educate patients to complete the prescribed course and to dispose of leftovers safely.

Delivery Across United Kingdom

Concluding Notes For Clinicians And Patients

Suprax (cefixime) remains a useful oral third‑generation cephalosporin with clear roles in selected community infections when local susceptibility supports its use.

Rising reduced susceptibility in Neisseria gonorrhoeae means cefixime is no longer a reliable first‑line option for uncomplicated gonorrhoea in many settings.

Consider cefixime for uncomplicated UTI, otitis media and pharyngitis when first‑line agents are unsuitable or when culture data indicate susceptibility.

Monitor renal function, counsel on common gastrointestinal adverse effects and advise immediate medical review for signs of severe allergy.

For patients needing convenient access, our online pharmacy offers Suprax without a prescription and discreet delivery to the United Kingdom in 5-14 days, subject to local regulations and purchase checks.

Report adverse events via the Yellow Card scheme and consult local antibiograms and NICE/UKHSA guidance for up‑to‑date prescribing decisions.

When in doubt, discuss the case with local microbiology or infectious disease colleagues to balance individual patient needs with stewardship obligations.